Pranela Rameshwar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7388843/publications.pdf

Version: 2024-02-01

159	7,425	57758	60623
papers	citations	44 h-index	81 g-index

166	166	166	9285
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cellâ€“derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Molecular Therapy - Nucleic Acids, 2013, 2, e126.	5.1	422
2	Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens. Journal of Immunology, 2003, 171, 3426-3434.	0.8	417
3	Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-Î³. Blood, 2006, 107, 4817-4824.	1.4	394
4	Gap Junctionâ€“Mediated Import of MicroRNA from Bone Marrow Stromal Cells Can Elicit Cell Cycle Quiescence in Breast Cancer Cells. Cancer Research, 2011, 71, 1550-1560.	0.9	388
5	Mesenchymal Stem Cells Protect Breast Cancer Cells through Regulatory T Cells: Role of Mesenchymal Stem Cell-Derived TGF-Î². Journal of Immunology, 2010, 184, 5885-5894.	0.8	342
6	Mesenchymal Stem Cellâ€“Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. Cancer Research, 2016, 76, 5832-5844.	0.9	306
7	Oxygen saturation in the bone marrow of healthy volunteers. Blood, 2002, 99, 394-394.	1.4	273
8	Functional Similarities Among Genes Regulated by Oct4 in Human Mesenchymal and Embryonic Stem Cells. Stem Cells, 2007, 25, 3143-3154.	3.2	228
9	Neurons Derived From Human Mesenchymal Stem Cells Show Synaptic Transmission and Can Be Induced to Produce the Neurotransmitter Substance P by Interleukin-1Î±. Stem Cells, 2005, 23, 383-391.	3.2	180
10	Specification of a Dopaminergic Phenotype from Adult Human Mesenchymal Stem Cells. Stem Cells, 2007, 25, 2797-2808.	3.2	168
11	Mesenchymal Stem Cells in Early Entry of Breast Cancer into Bone Marrow. PLoS ONE, 2008, 3, e2563.	2.5	143
12	Immunological properties of mesenchymal stem cells and clinical implications. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 1-8.	2.3	141
13	MicroRNAs regulate synthesis of the neurotransmitter substance P in human mesenchymal stem cell-derived neuronal cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15484-15489.	7.1	123
14	A Novel Model of Dormancy for Bone Metastatic Breast Cancer Cells. Cancer Research, 2013, 73, 6886-6899.	0.9	109
15	Brainâ€derived neurotrophic factor facilitates maturation of mesenchymal stem cellâ€derived dopamine progenitors to functional neurons. Journal of Neurochemistry, 2009, 110, 1058-1069.	3.9	108
16	Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget, 2015, 6, 1190-1201.	1.8	87
17	An Interdisciplinary Approach and Characterization of Neuronal Cells Transdifferentiated from Human Mesenchymal Stem Cells. Stem Cells and Development, 2007, 16, 811-826.	2.1	82
18	Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Scientific Reports, 2012, 2, 906.	3.3	82

#	Article	IF	Citations
19	Exosomes from differentially activated macrophages influence dormancy or resurgence of breast cancer cells within bone marrow stroma. Cell Death and Disease, 2019, 10, 59.	6.3	82
20	Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Letters, 2015, 367, 69-75.	7.2	79
21	Stem cell delivery of therapies for brain disorders. Clinical and Translational Medicine, 2014, 3, 24.	4.0	78
22	Facilitating Role of Preprotachykinin-I Gene in the Integration of Breast Cancer Cells within the Stromal Compartment of the Bone Marrow. Cancer Research, 2004, 64, 2874-2881.	0.9	74
23	Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 Expression in Glioblastoma Cells. Molecular Cancer Therapeutics, 2014, 13, 2399-2411.	4.1	72
24	Hematopoietic Regulation Mediated by Interactions Among the Neurokinins and Cytokines. Leukemia and Lymphoma, 1997, 28, 1-10.	1.3	69
25	RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4408-4413.	7.1	69
26	Mesenchymal Stem Cellâ€“Secreted Extracellular Vesicles Instruct Stepwise Dedifferentiation of Breast Cancer Cells into Dormancy at the Bone Marrow Perivascular Region. Cancer Research, 2021, 81, 1567-1582.	0.9	68
27	Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6. Frontiers in Immunology, 2017, 8, 1521.	4.8	67
28	SDF-1Î± regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. Blood, 2006, 108, 3245-3252.	1.4	64
29	Non-Coding RNAs as Mediators of Epigenetic Changes in Malignancies. Cancers, 2020, 12, 3657.	3.7	64
30	Distinct Roles of Glycogen Synthase Kinase (GSK)-3Î± and GSK-3Î² in Mediating Cardiomyocyte Differentiation in Murine Bone Marrow-derived Mesenchymal Stem Cells. Journal of Biological Chemistry, 2009, 284, 36647-36658.	3.4	61
31	Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17436-17441.	7.1	60
32	Enhancing Effect of IL-1Î± on Neurogenesis from Adult Human Mesenchymal Stem Cells: Implication for Inflammatory Mediators in Regenerative Medicine. Journal of Immunology, 2007, 179, 3342-3350.	0.8	60
33	Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. Therapeutic Delivery, 2012, 3, 997-1004.	2.2	60
34	Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. Frontiers in Bioscience - Landmark, 2004, 9, 1782.	3.0	58
35	Experimental Evidence for Bone Marrow as a Source of Nonhematopoietic Endometrial Stromal and Epithelial Compartment Cells in a Murine Model1. Biology of Reproduction, 2013, 89, 7.	2.7	58
36	Tolerance-like mediated suppression by mesenchymal stem cells in patients with dust mite allergyâ€“induced asthma. Journal of Allergy and Clinical Immunology, 2012, 129, 1094-1101.	2.9	57

#	Article	IF	Citations
37	Human Aging and Cancer: Role of miRNA in Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2018, 1056, 137-152.	1.6	55
38	Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study. Blood, 2001, 98, 2697-2706.	1.4	54
39	A paradoxical role for IFN-Î³ in the immune properties of mesenchymal stem cells during viral challenge. Experimental Hematology, 2005, 33, 796-803.	0.4	54
40	Shift toward Mechanical Isolation of Adipose-derived Stromal Vascular Fraction: Review of Upcoming Techniques. Plastic and Reconstructive Surgery - Global Open, 2016, 4, e1017.	0.6	54
41	Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P. Regulatory Peptides, 2003, 111, 169-178.	1.9	53
42	Bone Marrow Stroma Influences Transforming Growth Factor-Î² Production in Breast Cancer Cells to Regulate c-myc Activation of the Preprotachykinin-I Gene in Breast Cancer Cells. Cancer Research, 2004, 64, 6327-6336.	0.9	52
43	Cloning of Human Preprotachykinin-I Promoter and the Role of Cyclic Adenosine 5â€²-Monophosphate Response Elements in Its Expression by IL-1 and Stem Cell Factor. Journal of Immunology, 2001, 166, 2553-2561.	0.8	51
44	Novel therapeutic strategies for degenerative disc disease: Review of cell biology and intervertebral disc cell therapy. SAGE Open Medicine, 2018, 6, 205031211876167.	1.8	50
45	Investigating Breast Cancer Cell Behavior Using Tissue Engineering Scaffolds. PLoS ONE, 2015, 10, e0118724.	2.5	46
46	The dynamics of bone marrow stromal cells in the proliferation of multipotent hematopoietic progenitors by substance P: an understanding of the effects of a neurotransmitter on the differentiating hematopoietic stem cell. Journal of Neuroimmunology, 2001, 121, 22-31.	2.3	45
47	Enhanced osteogenic potential of mesenchymal stem cells from cortical bone: a comparative analysis. Stem Cell Research and Therapy, 2015, 6, 203.	5.5	44
48	Down-Regulation of MHC II in Mesenchymal Stem Cells at High IFN-Î³ Can Be Partly Explained by Cytoplasmic Retention of CIITA. Journal of Immunology, 2008, 180, 1826-1833.	0.8	41
49	Loss of RE-1 silencing factor in mesenchymal stem cell-derived dopamine progenitors induces functional maturity. Molecular and Cellular Neurosciences, 2008, 39, 285-290.	2.2	40
50	Targeting tumor microenvironment in cancer therapy. Cancer Letters, 2016, 380, 203-204.	7.2	39
51	The bone marrow niche in support of breast cancer dormancy. Cancer Letters, 2016, 380, 263-271.	7.2	39
52	Microenvironmental considerations in the application of human mesenchymal stem cells in regenerative therapies. Biologics: Targets and Therapy, 2008, 2, 699.	3.2	38
53	Mesenchymal stromal/stem cells in drug therapy: New perspective. Cytotherapy, 2017, 19, 19-27.	0.7	38
54	Nuclear Factor-ÎºB Is Central to the Expression of Truncated Neurokinin-1 Receptor in Breast Cancer: Implication for Breast Cancer Cell Quiescence within Bone Marrow Stroma. Cancer Research, 2007, 67, 1653-1659.	0.9	37

#	Article	IF	Citations
55	Non-coding RNA as mediators in microenvironmentâ€“breast cancer cell communication. Cancer Letters, 2016, 380, 289-295.	7.2	37
56	Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget, 2017, 8, 74494-74505.	1.8	35
57	Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. Experimental Hematology, 2002, 30, 1001-1009.	0.4	34
58	Synergy between the RE-1 Silencer of Transcription and NFÎºB in the Repression of the Neurotransmitter Gene TAC1 in Human Mesenchymal Stem Cells. Journal of Biological Chemistry, 2007, 282, 30039-30050.	3.4	33
59	Moving from the Laboratory Bench to Patientsâ€™ Bedside: Considerations for Effective Therapy with Stem Cells. Clinical and Translational Science, 2011, 4, 380-386.	3.1	33
60	The Microenvironmental Effect in the Progression, Metastasis, and Dormancy of Breast Cancer: A Model System within Bone Marrow. International Journal of Breast Cancer, 2012, 2012, 1-7.	1.2	33
61	Stem cells and regenerative medicine: accomplishments to date and future promise. Therapeutic Delivery, 2010, 1, 693-705.	2.2	32
62	Crosstalk between neurokinin receptors is relevant to hematopoietic regulation: cloning and characterization of neurokinin-2 promoter. Journal of Neuroimmunology, 2003, 138, 65-75.	2.3	31
63	Mesenchymal stem cell therapies in brain disease. Seminars in Cell and Developmental Biology, 2019, 95, 111-119.	5.0	31
64	High expression of miR-9 in CD133+glioblastoma cells in chemoresistance to temozolomide. Journal of Cancer Stem Cell Research, 2015, 3, 1.	1.1	30
65	Stromal Derived Growth Factor-1Î±: Another Mediator in Neural-Emerging Immune System through Tac1 Expression in Bone Marrow Stromal Cells. Journal of Immunology, 2007, 178, 2075-2082.	0.8	28
66	Role of human HGFIN/nmbin breast cancer. Breast Cancer Research, 2007, 9, R58.	5.0	28
67	Secretome within the bone marrow microenvironment: A basis for mesenchymal stem cell treatment and role in cancer dormancy. Biochimie, 2018, 155, 92-103.	2.6	28
68	T_{reg}/Th17 polarization by distinct subsets of breast cancer cells is dictated by the interaction with mesenchymal stem cells.. Journal of Cancer Stem Cell Research, 2014, 1, 1.	1.1	28
69	Methods of Mesenchymal Stem Cell Homing to the Bloodâ€“Brain Barrier. Methods in Molecular Biology, 2018, 1842, 81-91.	0.9	27
70	Epigenetic dynamics in cancer stem cell dormancy. Cancer and Metastasis Reviews, 2020, 39, 721-738.	5.9	26
71	Current Advances in the Treatment of Parkinsons Disease with Stem Cells. Current Neurovascular Research, 2007, 4, 99-109.	1.1	25
72	The RNAâ€binding protein Musashi 1 stabilizes the oncotachykinin 1 mRNA in breast cancer cells to promote cell growth. FASEB Journal, 2016, 30, 149-159.	0.5	25

#	Article	IF	Citations
73	Exogenous CXCL12 activates protein kinase C to phosphorylate connexin 43 for gap junctional intercellular communication among confluent breast cancer cells. Cancer Letters, 2013, 331, 84-91.	7.2	24
74	Stromal Derived Growth Factor-1alpha as a Beacon for Stem Cell Homing in Development and Injury. Current Neurovascular Research, 2005, 2, 319-329.	1.1	23
75	Tachykinins and Hematopoiesis. Clinica Chimica Acta, 2007, 385, 28-34.	1.1	23
76	Feline bone marrow-derived mesenchymal stromal cells (MSCs) show similar phenotype and functions with regards to neuronal differentiation as human MSCs. Differentiation, 2012, 84, 214-222.	1.9	23
77	Evaluation of a developmental hierarchy for breast cancer cells to assess risk-based patient selection for targeted treatment. Scientific Reports, 2018, 8, 367.	3.3	23
78	microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis. Current Cancer Therapy Reviews, 2011, 7, 176-183.	0.3	22
79	Bioactive Phospholipids Enhance Migration and Adhesion of Human Leukemic Cells by Inhibiting Heme Oxygenase 1 (HO-1) and Inducible Nitric Oxygenase Synthase (iNOS) in a p38 MAPK-Dependent Manner. Stem Cell Reviews and Reports, 2019, 15, 139-154.	5.6	22
80	Induction of Hypoxia-Inducible Factor-1Î± and Activation of Caspase-3 in Hypoxia-Reoxygenated Bone Marrow Stroma Is Negatively Regulated by the Delayed Production of Substance P. Journal of Immunology, 2001, 167, 4600-4608.	0.8	21
81	Pollen-induced antigen presentation by mesenchymal stem cells and T cells from allergic rhinitis. Clinical and Translational Immunology, 2013, 2, e7.	3.8	21
82	A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Molecular Therapy, 2017, 25, 2299-2308.	8.2	21
83	3D Bioprinting and Stem Cells. Methods in Molecular Biology, 2018, 1842, 93-103.	0.9	21
84	AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. American Journal of Cancer Research, 2011, 1, 701-15.	1.4	21
85	BONE MARROW FAILURE IN MALE RATS FOLLOWING TRAUMA/HEMORRHAGIC SHOCK (T/HS) IS MEDIATED BY MESENTERIC LYMPH AND MODULATED BY CASTRATION. Shock, 2006, 25, 12-16.	2.1	19
86	Cycling Quiescence in Temozolomide Resistant Glioblastoma Cells Is Partly Explained by microRNA-93 and -193-Mediated Decrease of Cyclin D. Frontiers in Pharmacology, 2019, 10, 134.	3.5	19
87	A method to generate human mesenchymal stem cell-derived neurons which express and are excited by multiple neurotransmitters. Biological Procedures Online, 2008, 10, 90-101.	2.9	19
88	G protein-coupled receptors in haematopoietic disruption. Expert Opinion on Biological Therapy, 2006, 6, 109-120.	3.1	18
89	Breast cancer cell dormancy in bone marrow: potential therapeutic targets within the marrow microenvironment. Expert Review of Anticancer Therapy, 2010, 10, 129-132.	2.4	18
90	A Review of Stem Cell Translation and Potential Confounds by Cancer Stem Cells. Stem Cells International, 2013, 2013, 1-8.	2.5	18

#	Article	IF	Citations
91	IFNÎ³ and B7-H1 in the immunology of mesenchymal stem cells. Cell Research, 2008, 18, 805-806.	12.0	16
92	G-Coupled Protein Receptors and Breast Cancer Progression: Potential Drug Targets. Mini-Reviews in Medicinal Chemistry, 2007, 7, 245-251.	2.4	15
93	Nuclear Factor-ÎºB Accounts for the Repressor Effects of High Stromal Cellâ€“Derived Factor-1Î± Levels on Tac1 Expression in Nontumorigenic Breast Cells. Molecular Cancer Research, 2007, 5, 373-381.	3.4	15
94	Breast Cancer Biology: The Multifaceted Roles of Mesenchymal Stem Cells. Journal of Oncology, 2008, 2008, 1-7.	1.3	14
95	Developmental Regulation ofTAC1in Peptidergic-Induced Human Mesenchymal Stem Cells: Implication for Spinal Cord Injury in Zebrafish. Stem Cells and Development, 2012, 21, 308-320.	2.1	14
96	A 3D Bioprinted Material That Recapitulates the Perivascular Bone Marrow Structure for Sustained Hematopoietic and Cancer Models. Polymers, 2021, 13, 480.	4.5	14
97	Immunostimulatory Effects of Mesenchymal Stem Cell-Derived Neurons: Implications for Stem Cell Therapy in Allogeneic Transplantations. Clinical and Translational Science, 2008, 1, 27-34.	3.1	13
98	Tac1 regulation by RNA-binding protein and miRNA in bone marrow stroma: Implication for hematopoietic activity. Brain, Behavior, and Immunity, 2008, 22, 442-450.	4.1	13
99	High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors. PLoS ONE, 2018, 13, e0199254.	2.5	13
100	Specific N-cadherinâ€“dependent pathways drive human breast cancer dormancy in bone marrow. Life Science Alliance, 2021, 4, e202000969.	2.8	13
101	Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia. Pharmaceuticals, 2021, 14, 641.	3.8	13
102	An in vitro method to study the effects of hematopoietic regulators during immune and blood cell development. Biological Procedures Online, 2007, 9, 56-64.	2.9	13
103	Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer: Targets and Therapy, 2010, 2, 1-11.	1.8	13
104	Neurokinin Receptors as Potential Targets in Breast Cancer Treatment. Current Drug Discovery Technologies, 2008, 5, 15-19.	1.2	12
105	Cancer Metabolism: Targeting metabolic pathways in cancer therapy. Cancer Letters, 2015, 356, 147-148.	7.2	12
106	Hypoxia-mediated changes in bone marrow microenvironment in breast cancer dormancy. Cancer Letters, 2020, 488, 9-17.	7.2	12
107	Temozolomide resistance and tumor recurrence: Halting the Hedgehog. Cancer Cell & Microenvironment, 2015, 2, .	0.8	12
108	The immune properties of mesenchymal stem cells. International Journal of Biomedical Science, 2007, 3, 76-80.	0.1	12

#	Article	IF	Citations
109	Structural similarity between the bone marrow extracellular matrix protein and neurokinin 1 could be the limiting factor in the hematopoietic effects of substance P. Canadian Journal of Physiology and Pharmacology, 2002, 80, 475-481.	1.4	11
110	A discussion on adult mesenchymal stem cells for drug delivery: pros and cons. Therapeutic Delivery, 2015, 6, 1335-1346.	2.2	11
111	Epigenetic Dysregulation at the Crossroad of Womenâ€™s Cancer. Cancers, 2019, 11, 1193.	3.7	11
112	Therapeutic Potential of Mesenchymal Stem Cells in Immune-Mediated Diseases. Advances in Experimental Medicine and Biology, 2019, 1201, 93-108.	1.6	11
113	Oncobiology and treatment of breast cancer in young women. Cancer and Metastasis Reviews, 2022, 41, 749-770.	5.9	11
114	Decoding epigenetic cell signaling in neuronal differentiation. Seminars in Cell and Developmental Biology, 2019, 95, 12-24.	5.0	10
115	Gap Junctions and Breast Cancer Dormancy. Trends in Cancer, 2020, 6, 348-357.	7.4	10
116	Stromal-derived factor-1Î± induces a non-canonical pathway to activate the endocrine-linked Tac1 gene in non-tumorigenic breast cells. Journal of Molecular Endocrinology, 2008, 40, 113-123.	2.5	9
117	Immune modulation by a cellular network of mesenchymal stem cells and breast cancer cell subsets: Implication for cancer therapy. Cellular Immunology, 2018, 326, 33-41.	3.0	9
118	An Enzyme-free Method for Isolation and Expansion of Human Adipose-derived Mesenchymal Stem Cells. Journal of Visualized Experiments, 2019, , .	0.3	9
119	Microenvironment at tissue injury, a key focus for efficient stem cell therapy: A discussion of mesenchymal stem cells. World Journal of Stem Cells, 2009, 1, 3.	2.8	9
120	An indirect role for the oncomir-519b in the expression of truncated neurokinin-1 in breast cancer cells. Experimental Cell Research, 2012, 318, 2604-2615.	2.6	8
121	Multipotent to Pluripotent Properties of Adult Stem Cells. Stem Cells International, 2013, 2013, 1-2.	2.5	8
122	The Tachykinergic System as Avenues for Drug Intervention. Recent Patents on CNS Drug Discovery, 2012, 7, 173-180.	0.9	7
123	Hierarchy of Breast Cancer Cells: Key to Reverse Dormancy for Therapeutic Intervention. Stem Cells Translational Medicine, 2014, 3, 782-786.	3.3	7
124	Verrucarin J inhibits ovarian cancer and targets cancer stem cells. Oncotarget, 2017, 8, 92743-92756.	1.8	7
125	Implication of Possible Therapies Targeted for the Tachykinergic System with the Biology of Neurokinin Receptors and Emerging Related Proteins. Recent Patents on CNS Drug Discovery, 2007, 2, 79-84.	0.9	6
126	Stem cell in alternative treatments for brain tumors: potential for gene delivery. Molecular and Cellular Therapies, 2014, 2, 24.	0.2	6

#	Article	IF	Citations
127	Enzyme-Free Isolation of Adipose-Derived Mesenchymal Stem Cells. Methods in Molecular Biology, 2018, 1842, 203-206.	0.9	6
128	Neuroimmune/Hematopoietic Axis with Distinct Regulation by the High-Mobility Group Box 1 in Association with Tachykinin Peptides. Journal of Immunology, 2020, 204, 879-891.	0.8	6
129	Potential Novel Targets in Breast Cancer. Current Pharmaceutical Biotechnology, 2009, 10, 148-153.	1.6	5
130	Current Thoughts on the Therapeutic Potential of Stem Cell. Methods in Molecular Biology, 2012, 879, 3-26.	0.9	5
131	Combination of Chemical and Neurotrophin Stimulation Modulates Neurotransmitter Receptor Expression and Activity in Transdifferentiating Human Adipose Stromal Cells. Stem Cell Reviews and Reports, 2019, 15, 851-863.	3.8	5
132	Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics. Cells, 2021, 10, 433.	4.1	5
133	NFÄB Targeting in Bone Marrow Mesenchymal Stem Cell-Mediated Support of Age-Linked Hematological Malignancies. Stem Cell Reviews and Reports, 2021, 17, 2178-2192.	3.8	5
134	Restoration of aged hematopoietic cells by their young counterparts through instructive microvesicles release. Aging, 2021, 13, 23981-24016.	3.1	5
135	Clinical Manufacturing of Human Mesenchymal Stromal Cells using a Potency-Driven Paradigm. Current Stem Cell Reports, 2022, 8, 61-71.	1.6	5
136	Tachykinins and neurokinin receptors in bone marrow functions: neural-hematopoietic link. Journal of Receptor, Ligand and Channel Research, 2010, 2010, 51.	0.7	4
137	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer: Basic and Clinical Research, 2015, 9s2, BCBCR.S29425.	1.1	4
138	Steroid-Mediated Decrease in Blood Mesenchymal Stem Cells in Liver Transplant could Impact Long-Term Recovery. Stem Cell Reviews and Reports, 2017, 13, 644-658.	5.6	4
139	Isolation and characterization of mesenchymal stem cells in orthopaedics and the emergence of compact bone mesenchymal stem cells as a promising surgical adjunct. World Journal of Stem Cells, 2020, 12, 1341-1353.	2.8	4
140	Defect in the lymphoid compartment might account for CD8+-mediated effects in the pathophysiology of pure red cell aplasia. Clinical Immunology, 2003, 108, 248-256.	3.2	3
141	Functions and Roles of Proteins: Diabetes as a Paradigm. Progress in Biophysics and Molecular Biology, 2014, 114, 2-7.	2.9	3
142	An Update on the Therapeutic Potential of Stem Cells. Methods in Molecular Biology, 2018, 1842, 3-27.	0.9	3
143	Effects by anthrax toxins on hematopoiesis: A key role for cytokines as mediators. Cytokine, 2012, 57, 143-149.	3.2	2
144	Would cancer stem cells affect the future investment in stem cell therapy. World Journal of Experimental Medicine, 2012, 2, 26.	1.7	2

#	Article	IF	Citations
145	3D bioprinting as a designer organoid to assess pathological processes in translational medicine. Journal of 3D Printing in Medicine, 2022, 6, 37-46.	2.0	2
146	Is reduction of tumor burden sufficient for the 21st century?. Cancer Letters, 2015, 356, 149-155.	7.2	1
147	Therapeutic approaches to overcome temozolomide resistance in glioblastoma. , 2021, , 507-545.		1
148	Hematological Humanization of Immune-Deficient Mice. Methods in Molecular Biology, 2021, 2224, 195-202.	0.9	1
149	Exosomes in the Healthy and Malignant Bone Marrow Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1350, 67-89.	1.6	1
150	Implications for breast cancer dormancy in other areas of medicine. Breast Cancer: Targets and Therapy, 2012, 4, 193.	1.8	0
151	Functions and Roles of a Protein-Associated Factor. Cell Biochemistry and Biophysics, 2014, 68, 577-582.	1.8	0
152	Cancer Stem Cells: Issues with In Vitro Expansion and Model Systems. , 2016, , 127-142.		0
153	Featuring the guest editors: Special issue tumor microenvironment. Cancer Letters, 2016, 380, 201-202.	7.2	0
154	Constitutive Expression of Inducible Cyclic Adenosine Monophosphate Early Repressor (ICER) in Cycling Quiescent Hematopoietic Cells: Implications for Aging Hematopoietic Stem Cells. Stem Cell Reviews and Reports, 2017, 13, 116-126.	5.6	0
155	Cancer stem cell gene profile getting closer to the clinic to enhance precise treatment. EBioMedicine, 2019, 42, 22-23.	6.1	0
156	Purinergic signaling in bone marrow stem cell mobilization. Purinergic Signalling, 2020, 16, 255-256.	2.2	0
157	Restoration of Aged Hematopoietic Cells by Their Young Counterparts Through Instructive Microvesicle Release. SSRN Electronic Journal, 0, , .	0.4	0
158	The HGFIN Gene Mediates Cell Cycle Quiescence of CD34+/CD38-: Implications for Hematopoietic Stem Cell Expansion and Gene Therapy.. Blood, 2004, 104, 1698-1698.	1.4	0
159	Expression of glucocorticoid and androgen receptors in bone marrow-derived hematopoietic and non-hematopoietic murine endometrial cells. F&S Science, 2022, , .	0.9	0